These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38599779)

  • 1. Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19.
    Zhang H; Xiaojiao T; Chen J; Zhang Z; Wang C; Shi H; Li Y; Li J; Kang Y; Jin X; Liao X
    BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38599779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.
    Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F
    Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
    Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
    BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azvudine versus Paxlovid in COVID-19: A systematic review and meta-analysis.
    Amani B; Amani B
    Rev Med Virol; 2024 Jul; 34(4):e2551. PubMed ID: 38849982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study.
    Zhang H; Tan X; Zhang Z; Wang C; Shi H; Li Y; Li J; Kang Y; Jin X; Liao X
    BMC Infect Dis; 2024 Jun; 24(1):597. PubMed ID: 38890575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the antiviral medications azvudine and nirmatrelvir-ritonavir in treating COVID-19 in patients with hematological malignancies.
    Zeng Z; Li F; Zhong M; Zhu L; Chen W; Wang X
    Clinics (Sao Paulo); 2024; 79():100406. PubMed ID: 39059144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study.
    Kapar A; Xie S; Guo Z; Nan Y; Du Y; Yin X; Gong T; Gu X; Zhou Y; Lu W; Yang A; Luo Z; Dai J; Wang K; Zhao S; Wang K
    Expert Rev Anti Infect Ther; 2024 Jul; 22(7):569-577. PubMed ID: 38822541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients.
    Su P; Yang CX; Wang XG
    BMC Infect Dis; 2024 Jan; 24(1):44. PubMed ID: 38172735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
    Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
    Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing.
    Xie H; Wang Y; Xu Y; Wang L; Fan J; Pan S; Shi C; Liu X; Gao X; Guo X; Yu S; Liu J; Zhang D; Yang Y; Zhang H; Wang J; Wu A; Liu X; Liu J; Zhu H; Zhou X; Tian X; Wang M
    Sci Rep; 2024 Oct; 14(1):23974. PubMed ID: 39402091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
    Deng G; Li D; Sun Y; Jin L; Zhou Q; Xiao C; Wu Q; Sun H; Dian Y; Zeng F; Pan P; Shen M
    J Med Virol; 2023 Apr; 95(4):e28756. PubMed ID: 37185838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
    Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P
    EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.
    Zhao X; Cheng Y; Zhang M; Qianda B; Zhouma B; Yangzhen B; Zheng Y; Zhang S; Zhao H
    Infect Drug Resist; 2023; 16():6053-6060. PubMed ID: 37719651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
    Zhou Y; Liu Y; Jiang L; Zhang R; Zhang H; Shi Q; Yang Z; Mao Y; Liu S; Yang Z; Ding J; Zhou Y; Ren B; He L; Zhao X; Li W; Li S; Liu D
    J Med Virol; 2023 Dec; 95(12):e29318. PubMed ID: 38112106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
    Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
    Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.
    Hu CY; Cui WS; Lei Y; Tang YW; Zhang YY; Su QM; Peng F; Zeng YF; Song JL; Luo CN; Zhou Y; Li XY; Zhao ZX
    Infect Drug Resist; 2023; 16():7797-7808. PubMed ID: 38148771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals.
    Gao Y; Dong Y; Bu Q; Gong Z; Wang W; Zhou Z; Gao Y; Liu L; Wu M; Zhang J; Liang L; Li H; Jiang M; Luo Z; Ma Y; Zhang X; Hu Z
    Influenza Other Respir Viruses; 2024 Sep; 18(9):e70006. PubMed ID: 39284764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
    Zhou Z; Zheng H; Xiao G; Xie X; Rang J; Peng D
    BMC Infect Dis; 2024 Jan; 24(1):47. PubMed ID: 38177982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
    Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
    Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.